Abbott (ABT: Quote) said its scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism, or EULAR, Congress in Berlin, Germany, from June 6-9, 2012.
The presentations include two of the longest open-label extension studies in rheumatoid arthritis, or RA, featuring long-term data for disease activity and radiographic inhibition. Data will also be presented on investigational indications in axial and peripheral spondyloarthritis, moderate to severe polyarticular juvenile idiopathic arthritis, ankylosing spondylitis and health economics research.
Data being presented at EULAR include the comprehensive 10-year data for treatment of moderate to severe, long-standing RA in the DE019 trial and in the DE020 follow-up study. DE020 will be presented in a publication, while DE019 will be presented as a poster on June 9.
Besides, data will be presented for ABILITY-I, the first, multi-national Phase 3 study evaluating the use of an anti-tumor necrosis factor medication in patients with active non-radiographic axial SpA - a debilitating condition closely related to AS that primarily presents with chronic back pain and stiffness, and can be accompanied by the presence of arthritis, and inflammation in the eye and/or gastrointestinal tract.
The initial results will be presented from ABILITY-2, the first Phase 3 study investigating the use of an anti-TNF medication in patients with active peripheral SpA that don't have a diagnosis of psoriatic arthritis.
| || |
| To receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com